Regenxbio hit with another clinical hold for Hunter syndrome gene therapy

RegulatoryrejectedNegative

AI Analysis

Summary

Regenxbio's Hunter syndrome gene therapy program received its second clinical hold in 2026, prompting the company to suspend near-term FDA approval plans.

Outcome Details

Second clinical hold issued in 2026; company no longer expects near-term FDA approval filing

Importance:8/10

Sentiment:

-0.90

clinical holdgene therapyregulatory setbackHunter syndrome

Related Companies

$RGNX

Read the original article

Published by Endpoints News on August 24, 2026 3:17 PM

Read Original